As, in this study, we revealed 22% of SCCs and 16% of AC/UrCs AR-positive, anti-AR therapy might address a significant proportion of patients, and we are looking forward to future clinical trials also including aberrant differentiated bladder cancers. The gene discussed is AR; the disease is urinary bladder carcinoma.